A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer.

Kunning WangEnxiao LiRita A BusuttilJoseph C KongSharon PattisonJoseph J Y SungJun YuEmad M El-OmarJulie A SimpsonAlex Boussioutas

Published in: Therapeutic advances in medical oncology (2020)

Our results support the consideration of Lauren subtype when prescribing systemic chemotherapy for GC, particularly for MGC or DGC, which may not benefit from chemotherapy. Lauren classification should be considered to stratify chemotherapy regimens to GC patients in future clinical trials, with particular relevance to MGC or DGC, which is more difficult to treat with current regimens.

Keyphrases

locally advanced
clinical trial
primary care
end stage renal disease
chronic kidney disease
ejection fraction
early stage
squamous cell carcinoma
machine learning
newly diagnosed
emergency department
prognostic factors
deep learning
chemotherapy induced
open label
mass spectrometry